One Of The Five Cyclos Is Five-membered And Includes Ring Chalcogen (e.g., Codeine, Morphine, Etc.) Patents (Class 514/282)
  • Patent number: 10702480
    Abstract: An abuse resistant oral pharmaceutical composition, comprising: a barrier layer, comprising a first polymer; a diffusion layer, comprising a second polymer, substantially covering the barrier layer, wherein the diffusion layer is bonded to the barrier layer and comprises a drug that is substantially homogeneously distributed within the second polymer and diffuses from the diffusion layer within the gastrointestinal (GI) tract; and optionally an expansion layer comprising an expandable polymer, wherein the expansion layer is substantially covered by the barrier layer. Methods of making the same and methods of using the same are also provided.
    Type: Grant
    Filed: May 9, 2014
    Date of Patent: July 7, 2020
    Assignee: OHEMO Life Sciences, Inc.
    Inventors: Manish S. Shah, Ray J. DiFalco
  • Patent number: 10695343
    Abstract: A method for inducing a sustained immune response in humans or animal patient suffering from human immunodeficiency virus (HIV) acquired immune deficiency syndrome (AIDS, autoimmune disease, cancer, inflammation, and neurodegenerative diseases comprises daily administration to such patients a single oral tablet, rapidly dissolving film, capsule, liquid or cream dose of an Immediate release naltrexone composition comprising between about 0.01 to about 10 mg of naltrexone. In order to provide a benefit the naltrexone must be an Immediate release composition comprising between about 0.01 and about 10 mg of naltrexone.
    Type: Grant
    Filed: October 8, 2018
    Date of Patent: June 30, 2020
    Inventors: Noreen Griffin, Fengping Shan, Nicholas Plotnikoff
  • Patent number: 10695324
    Abstract: The present invention generally relates to a method of treating or preventing an endoplasmic reticulum stress disorder in subjects, such as a method of treating or preventing Wolfram syndrome.
    Type: Grant
    Filed: September 30, 2019
    Date of Patent: June 30, 2020
    Assignee: Washington University
    Inventors: Fumihiko Urano, Simin Lu
  • Patent number: 10696684
    Abstract: In certain embodiments the invention is directed to a process for preparing an oxycodone hydrochloride composition having less than 25 ppm of 14-hydroxycodeinone.
    Type: Grant
    Filed: November 20, 2019
    Date of Patent: June 30, 2020
    Assignees: PURDUE PHARMA L.P., PURDUE PHARMACEUTICALS L.P, RHODES TECHNOLOGIES
    Inventors: Robert Chapman, Lonn S. Rider, Qi Hong, Donald Kyle, Robert Kupper
  • Patent number: 10695342
    Abstract: Abuse-resistant opioid compounds, drug delivery systems, pharmaceutical compositions comprising an opioid covalently bound to a chemical moiety are provided. Methods of delivering an active ingredient to a subject and methods of preventing opioid abuse are also provided.
    Type: Grant
    Filed: February 13, 2017
    Date of Patent: June 30, 2020
    Assignees: ALBANY MOLECULAR RESEARCH, INC., 3ST RESEARCH LLC
    Inventors: Matthew Surman, John K. Thottathil, Kathryn Golden, Paolo Pasetto, Xiaomin Jin, Xiaowu Jiang, Fatoumata Camara
  • Patent number: 10689389
    Abstract: In certain embodiments the invention is directed to a process for preparing an oxycodone hydrochloride composition having less than 25 ppm of 14-hydroxycodeinone.
    Type: Grant
    Filed: August 30, 2019
    Date of Patent: June 23, 2020
    Assignees: PURDUE PHARMA L.P., PURDUE PHARMACEUTICALS L.P., RHODES TECHNOLOGIES
    Inventors: Robert Chapman, Lonn S. Rider, Qi Hong, Donald Kyle, Robert Kupper
  • Patent number: 10653632
    Abstract: The present disclosure relates generally to binder powders for use in powder material processing and processes for their preparation. The disclosure further relates to binder powders for use in making solid powder compact forms, solid powder compact forms containing said binder powders and methods for making solid powder compact forms.
    Type: Grant
    Filed: February 28, 2012
    Date of Patent: May 19, 2020
    Assignee: Monash University
    Inventors: David Morton, Laurence Orlando, Tony Qi Zhou, Louise Chia-Hua Ho
  • Patent number: 10638786
    Abstract: Methods and compositions are provided directed to decreasing visceral fat in subjects. Visceral fat is directly linked to cardiovascular and metabolic disease risk. The methods describe a calorie restricted diet of specific percentages of food elements to be consumed within a specific time period each day. Calorie restriction and nutrient percentages take into consideration average daily normal activity of subjects as well as baseline health metrics including estimated amount of visceral fat. Remarkable results are obtained since visceral fat is targeted for reduction, thereby markedly reducing the risk of cardiovascular and metabolic disease.
    Type: Grant
    Filed: August 16, 2017
    Date of Patent: May 5, 2020
    Assignee: Zolighter, LLC
    Inventors: Jessica Barnes, Gerald Dembrowski
  • Patent number: 10632205
    Abstract: A pharmaceutical paste composition comprising an active ingredient such as an addictive substance, a controlled release agent, and a pharmaceutically suitable aqueous or non-aqueous carrier. The composition may comprise one or more of a clay, or an oily, waxy, or fatty substance. The composition may be filled into a capsule or other dispensing device. The composition may reduce dose dumping of an active ingredient. Methods of making and using the composition are also described.
    Type: Grant
    Filed: May 29, 2015
    Date of Patent: April 28, 2020
    Assignee: INTELLIPHARMACEUTICS CORP
    Inventors: Isa Odidi, Amina Odidi
  • Patent number: 10604488
    Abstract: The present invention provides (+)-morphinans comprising Toll-like receptor 9 (TLR9) antagonist activity, as well as methods for using the (+)-morphinans to treat pain. Also provided are pharmaceutical combination compositions comprising a (+)-morphinan and an opioid agonist/monoamine reuptake inhibitor, as well as methods for using the combination compositions to treat pain.
    Type: Grant
    Filed: September 2, 2016
    Date of Patent: March 31, 2020
    Assignee: Mallinckrodt LLC
    Inventors: Bobby N. Trawick, David W. Berberich, Christopher W. Grote
  • Patent number: 10588973
    Abstract: The embodiments provide a percutaneous absorption composition for a basic medicament having improved transdermal absorbability. The percutaneous absorption composition comprises a sorbic acid and/or a metal sorbate as a percutaneous absorption promotor. The molar ration of the sorbic acid and/or the metal sorbate to the basic medicament is 0.5-2.5. The composition of the present disclosure may further comprise a basic component.
    Type: Grant
    Filed: April 23, 2018
    Date of Patent: March 17, 2020
    Assignee: MEDRx Co., LTD
    Inventors: Yasushi Miwa, Hidetoshi Hamamoto, Naoya Akazawa
  • Patent number: 10576045
    Abstract: The present invention provides a pharmaceutical composition comprising a selective serotonin reuptake inhibitor (SSRI) and a norepinephrine reuptake inhibitor (NRI), particularly, fluoxetine and reboxetine, for treating obesity. Surprisingly, the inventor of the present invention discovered that use of especially low doses of the active compounds, particularly, at most 6 mg/day of reboxetine and at most 20 mg/day of fluoxetine, wherein the reboxetinerfluoxetine ratio is from about 1:4 to about 1:6, induces an effective weight loss in obese patients. Advantageously, the combinations of the present invention include very low doses of the active ingredients, thereby decreasing possible drug-drug interactions and adverse drug reaction.
    Type: Grant
    Filed: February 15, 2012
    Date of Patent: March 3, 2020
    Inventor: Nir Barak
  • Patent number: 10561628
    Abstract: An object of the present invention is to provide [(1R,5S,6S)-6-(aminomethyl)-3-ethylbicyclo[3.2.0]hept-3-en-6-yl]acetic acid monobenzenesulfonate as a stabilized pharmaceutical solid preparation, and also to provide a method for preparing the stabilized pharmaceutical solid preparation. The object can be attained by a pharmaceutical solid preparation comprising [(1R,5S,6S)-6-(aminomethyl)-3-ethylbicyclo[3.2.0]hept-3-en-6-yl]acetic acid monobenzenesulfonate which is a compound represented by the following formula (I) in combination with (i) one or two or more excipients, (ii) one or two or more disintegrants, and (iii) a specific antioxidant.
    Type: Grant
    Filed: March 17, 2016
    Date of Patent: February 18, 2020
    Assignee: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Shinichiro Tajiri, Jin Hisazumi, Shinji Yoshinaga, Hiroyuki Fujimori, Hiroaki Arai
  • Patent number: 10555916
    Abstract: A method of treating a pervasive development disorder in a subject includes administering to the subject an amount of an NMDAR antagonist effective to ameliorate biochemical and functional abnormalities in the subject associated with loss-of-function mutations of the gene encoding methyl-CpG binding protein 2 (MeCP2).
    Type: Grant
    Filed: January 27, 2014
    Date of Patent: February 11, 2020
    Assignee: CASE WESTERN RESERVE UNIVERSITY
    Inventor: David M. Katz
  • Patent number: 10517841
    Abstract: 5-HT receptor agonists are useful in the treatment of a variety of diseases. Provided herein are methods of treating and/or reducing the occurrence of respiratory depression caused by an opioid in a human patient or patient population using a 5-HT receptor agonist, such as, for example, a 5-HT4 agonist (e.g., fenfluramine). Methods of stimulating one or more 5-HT4 receptors in the brain of a patient undergoing treatment with an opioid, wherein the patient is at risk of respiratory depression, by administering a 5-HT4 agonist (e.g., fenfluramine) to a subject in need thereof are provided. Pharmaceutical compositions for use in practicing the subject methods are also provided.
    Type: Grant
    Filed: June 5, 2019
    Date of Patent: December 31, 2019
    Assignee: ZOGENIX INTERNATIONAL LIMITED
    Inventors: Bradley S. Galer, Carl L. Faingold, Parthena Martin
  • Patent number: 10449190
    Abstract: The invention describes pharmaceutical compounds and compositions comprised of a ligand attached to opioids in a manner that substantially decreases or deters the potential for opioid abuse, addiction, illicit and illegal use, and overdose. When delivered at the proper dosage, the pharmaceutical composition provides therapeutic activity similar to that of the parent active agent.
    Type: Grant
    Filed: March 29, 2017
    Date of Patent: October 22, 2019
    Inventor: John K. Thottathil
  • Patent number: 10449235
    Abstract: Some embodiments are directed to the use of creatine kinase or fragments thereof which induce analgesia, and also to the use of pharmaceutical compositions including the same, to relieve pain.
    Type: Grant
    Filed: March 7, 2016
    Date of Patent: October 22, 2019
    Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITÉ DE STRASBOURG
    Inventors: Yannick Goumon, Jinane Mouheiche, Alexis Laux-Biehlmann, Pierrick Poisbeau, Nisrine Kamoun
  • Patent number: 10441657
    Abstract: An abuse deterrent pharmaceutical composition including a pharmaceutically active ingredient; an acid soluble ingredient; and a buffering ingredient; wherein the acid soluble ingredient and the buffering ingredient retard release of the active pharmaceutical ingredient when the composition is ingested in excess of an intended dosage.
    Type: Grant
    Filed: May 8, 2017
    Date of Patent: October 15, 2019
    Assignee: ABUSE DETERRENT PHARMACEUTICALS, LLC
    Inventors: Albert W. Brzeczko, R. Gary Hollenbeck
  • Patent number: 10441537
    Abstract: Methods of treating a heart condition include administering by inhalation an effective amount of at least one antiarrhythmic pharmaceutical agent to a patient in need thereof. Nebulized drug product and kits are also contemplated.
    Type: Grant
    Filed: May 10, 2018
    Date of Patent: October 15, 2019
    Assignee: InCarda Therapeutics, Inc.
    Inventors: Carlos Schuler, Rangachari Narasimhan, Luiz Belardinelli, Prashanti Madhavapeddi
  • Patent number: 10441585
    Abstract: Immediate release, oral, pharmaceutical formulation comprising nalbuphine or a pharmaceutically acceptable salt thereof, and at least one hydrophilic granulation carrier, one hydrophilic binder and one lubricant.
    Type: Grant
    Filed: June 1, 2016
    Date of Patent: October 15, 2019
    Assignee: DEBREGEAS ET ASSOCIES PHARMA
    Inventors: Christophe Lebon, Pascal Suplie, David Olivier Paul
  • Patent number: 10406153
    Abstract: The invention is directed to processes for the preparation of benzhydrocodone hydrochloride. More particularly, the invention is directed to processes for a one-pot synthesis of benzhydrocodone hydrochloride of improved yield and/or purity.
    Type: Grant
    Filed: August 31, 2017
    Date of Patent: September 10, 2019
    Assignee: Noramco, Inc.
    Inventors: Wen-Chun Zhang, Bruce P. Johnson
  • Patent number: 10403170
    Abstract: The present disclosure relates to compositions, kits, uses, systems and methods for treating overweight and obesity using naltrexone plus bupropion, preferably in combination with a comprehensive web-based and/or telephone-based weight management program, and preferably in subjects at increased risk of adverse cardiovascular outcomes.
    Type: Grant
    Filed: April 19, 2017
    Date of Patent: September 3, 2019
    Assignee: Nalpropion Pharmaceuticals, Inc.
    Inventors: Preston Klassen, Kristin Taylor
  • Patent number: 10376584
    Abstract: Stable pharmaceutical compositions useful for administering methylnaltrexone are described, as are methods for making the same. Kits, including these pharmaceutical compositions, also are provided.
    Type: Grant
    Filed: March 30, 2017
    Date of Patent: August 13, 2019
    Assignee: Progenics Pharmaceuticals, Inc.
    Inventors: Suketu P. Sanghvi, Thomas A. Boyd
  • Patent number: 10370382
    Abstract: There is provided a novel process for the preparation of a compound of formula (I), wherein R1 is as described in the description, by demethylation of a corresponding O-methyl derivative.
    Type: Grant
    Filed: July 26, 2016
    Date of Patent: August 6, 2019
    Assignee: Cambrex Charles City, Inc.
    Inventors: Pär Holmberg, Michael Robert Tracey, Zhiming Eric Dong
  • Patent number: 10351574
    Abstract: Compositions comprising hydrocodone benzoic acid enol ester to form novel prodrugs including hydrocodone benzoic acid enol ester salts, and various polymorphs. Also provided are processes for the preparation of hydrocodone benzoic acid enol ester salts, and various polymorphs.
    Type: Grant
    Filed: October 12, 2017
    Date of Patent: July 16, 2019
    Assignee: KemPharm, Inc.
    Inventors: Travis Mickle, Sven Guenther, Christal Mickle, Guochen Chi, Jaroslaw Kanski, Andrea K. Martin, Bindu Bera
  • Patent number: 10314838
    Abstract: The invention relates to a composition comprising buprenorphine and a ? opioid receptor antagonist, wherein the composition is characterized by an Agonist Antagonist Activity Index (AAnAI) of between about 0.7 and about 2.2; wherein; AAnAI = [ c ma ? ? x ? ( BUP ) / EC 50 ] [ c ma ? ? x ? ( ANTAGONIST ) / IC 50 ] .
    Type: Grant
    Filed: September 28, 2017
    Date of Patent: June 11, 2019
    Assignee: Alkermes Pharma Ireland Limited
    Inventors: Daniel Deaver, Elliot Ehrich
  • Patent number: 10300015
    Abstract: The present invention relates to a homogeneous, stable, and palatable pharmaceutical solution comprising baclofen, sorbitol and naltrexone.
    Type: Grant
    Filed: June 5, 2014
    Date of Patent: May 28, 2019
    Assignee: Pharnext
    Inventors: Daniel Cohen, Ilya Chumakov, Serguei Nabirochkin, Viviane Bertrand
  • Patent number: 10292972
    Abstract: A pharmaceutical composition containing an anticancer compound, named isopicrinine, isolated from the plant Rhazya Stricta. The pharmaceutical composition may contain a salt, an analog, a derivative, and/or the prodrug of isopicrinine. A method of treating cancer with the pharmaceutical composition is disclosed. A method of extracting isopicrinine is also disclosed.
    Type: Grant
    Filed: October 26, 2017
    Date of Patent: May 21, 2019
    Assignee: King Abdulaziz University
    Inventors: Jamal Sabir M. Sabir, Abdullah Y. Obaid, Nahid H. Hajrah, Waseem Mohammed, Zainab H. Abdul-Hameed, Walied M. Alarif, Roop Singh Bora, Seif-Eldin N. Ayyad, Nouf Saeed A. Al-Abbas, Abdulkader M. Shaikh Omer, Mohammed Zainy Mutawakil, Neil Hall, Kulvinder Singh Saini
  • Patent number: 10278967
    Abstract: The present disclosure provides acetate salts of buprenorphine, and its anhydrates, solvates, hydrates, and crystalline forms thereof, where the acetate salts of buprenorphine are essentially free of impurities. The disclosure further provides method of preparing the acetate salts, buprenorphine free base prepared from the acetate salts, other salts prepared from the free base, and pharmaceutical compositions thereof essentially free of impurities.
    Type: Grant
    Filed: February 12, 2018
    Date of Patent: May 7, 2019
    Assignee: Rhodes Technologies
    Inventors: C. Frederick M. Huntley, Erik Wayne Kataisto, Helge Alfred Reisch, Archana Sharma
  • Patent number: 10258235
    Abstract: The present invention provides a method for assessing bowel function in a patient, comprising providing the patient with a numeric analog scale for at least one parameter which is a measure of bowel function; causing the patient to indicate on the numeric analog scale the amount and/or intensity of the parameter being experienced; and observing the amount and/or intensity of the at least one parameter indicated on the numeric analog scale in order to assess bowel function.
    Type: Grant
    Filed: February 28, 2006
    Date of Patent: April 16, 2019
    Assignee: Purdue Pharma L.P.
    Inventors: Petra Leyendecker, Michael Hopp, Axel Drews
  • Patent number: 10258616
    Abstract: The present invention relates to prolonged release pharmaceutical dosage forms comprising hydromorphone or a pharmaceutically acceptable salt thereof and naloxone or a pharmaceutically acceptable salt thereof for use in the treatment of pain.
    Type: Grant
    Filed: November 10, 2017
    Date of Patent: April 16, 2019
    Assignee: Euro-Celtique S.A.
    Inventors: Helen Kathleen Danagher, Hassan Mohammad, Malcolm Walden, Geoffrey Gerard Hayes, Jonathon Oliver Whitehouse, Thinnayam Naganathan Krishnamurthy, Ricardo Alberto Vargas Rincon
  • Patent number: 10259819
    Abstract: In certain embodiments the invention is directed to a process for preparing an oxycodone hydrochloride composition having less than 25 ppm of 14-hydroxycodeinone.
    Type: Grant
    Filed: September 29, 2017
    Date of Patent: April 16, 2019
    Assignees: PURDUE PHARMA L.P., THE P.F. LABORATORIES, INC., PURDUE PHARMACEUTICALS L.P., RHODES TECHNOLOGIES
    Inventors: Robert Chapman, Lonn S. Rider, Qi Hong, Donald Kyle, Robert Kupper
  • Patent number: 10238647
    Abstract: Disclosed are compositions for affecting weight loss comprising a first compound and a second compound, where the first compound is an opioid antagonist and the second compound causes increased agonism of a melanocortin 3 receptor (MC3-R) or a melanocortin 4 receptor (MC4-R) compared to normal physiological conditions. Also disclosed are methods of affecting weight loss, increasing energy expenditure, increasing satiety in an individual, or suppressing the appetite of an individual, comprising identifying an individual in need thereof and treating that individual to antagonize opioid receptor activity and to enhance ?-MSH activity.
    Type: Grant
    Filed: September 26, 2016
    Date of Patent: March 26, 2019
    Assignee: Nalpropion Pharmaceuticals, Inc.
    Inventors: Eckard Weber, Michael Alexander Cowley
  • Patent number: 10226457
    Abstract: Disclosed in certain embodiments is a method of treating or preventing an opioid induced adverse pharmacodynamic response comprising administering to a patient in need thereof an effective amount of buprenorphine.
    Type: Grant
    Filed: December 8, 2017
    Date of Patent: March 12, 2019
    Assignee: Purdue Pharma L.P.
    Inventors: Michele Hummel, Donald J. Kyle, Garth Whiteside
  • Patent number: 10226456
    Abstract: Abuse-resistant opioid compounds, drug delivery systems, pharmaceutical compositions comprising an opioid covalently bound to a chemical moiety are provided. Methods of delivering an active ingredient to a subject and methods of preventing opioid abuse are also provided.
    Type: Grant
    Filed: April 27, 2016
    Date of Patent: March 12, 2019
    Assignee: 3ST Research LLC
    Inventor: John K. Thottathil
  • Patent number: 10216900
    Abstract: Information regarding a patient's physiological signs is provided in real-time, in particular in conjunction with drug administration to the patient. A patient data input obtains patient data of a monitored patient. A drug identification input obtains drug administration data identifying a drug administered to the patient and the time of administration of the drug to the patient. A drug information input obtains drug information about the identified drug, including drug side effects and/or drug-drug interactions and/or drug-disease contraindications. A processing unit determines time-resolved monitoring information based on the obtained patient data, drug administration data and drug information. The monitoring information is dynamically adapted and one or more physiological signs of the patient that are most critical to monitor over time are indicated. An output interface outputs the monitoring information.
    Type: Grant
    Filed: September 18, 2015
    Date of Patent: February 26, 2019
    Assignee: KONINKLIJKE PHILIPS N.V.
    Inventors: Murtaza Bulut, Charles Frederik Sio
  • Patent number: 10206921
    Abstract: Methods for treating a central nervous system (CNS) injury in a subject are provided. Aspects of the methods include administering to the subject an effective amount of gamma aminobutyric acid (GABA) receptor signaling inhibitor to treat the subject for the CNS injury. Also provided are compositions finding use in embodiments of the methods. Methods and compositions of the invention find use in the treatment of a variety of different CNS injuries, including but not limited to, treating a subject for CNS injury associated with the occurrence of stroke.
    Type: Grant
    Filed: June 3, 2010
    Date of Patent: February 19, 2019
    Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Stanley T. Carmichael, Istvan Mody, Andrew Clarkson, Ben Huang
  • Patent number: 10201174
    Abstract: The present invention relates to processes for removal of Michael acceptors from certain compositions wherein the composition is treated with a thiol-containing compound under conditions sufficient to remove Michael acceptors and the resulting thiol-Michael adducts. Certain embodiments of the present invention enable quantification and/or removal of Michael acceptors and/or Michael acceptor precursors.
    Type: Grant
    Filed: August 1, 2016
    Date of Patent: February 12, 2019
    Assignee: Controlled Chemicals, Inc.
    Inventors: Jules A. Shafer, Vladislav V. Telyatnikov, Hao Wang
  • Patent number: 10201553
    Abstract: A pharmaceutical composition for the prevention, protective effect, or treatment of a neurodegenerative condition, is provided. The composition includes a combination of cannabidiol water soluble powder; astaxanthin; alpha-glyceryl phosphoryl choline; and phosphatidyl serine. Optional supporting ingredients may be provided also.
    Type: Grant
    Filed: July 17, 2017
    Date of Patent: February 12, 2019
    Assignee: H Smart Inc.
    Inventors: Dianna Steinberg, Tim Altvater
  • Patent number: 10195219
    Abstract: The present invention is directed to compositions and methods for the treatment of cancers, particularly cancers of epithelial origin. Therapy with a plurality of nutraceutical, non-chemotherapeutic and chemotherapeutic agents, that together target a plurality of cancer-supportive processes in a patient are disclosed. Among other things, the present invention encompasses the insight that redundant targeting of multiple such pathways provides effective treatment of various cancer, including late-stage cancers, metastasized cancers, and/or cancers that have failed treatment with traditional chemotherapy and/or other therapeutic modalities.
    Type: Grant
    Filed: April 11, 2014
    Date of Patent: February 5, 2019
    Assignee: NED Biosystems, Inc.
    Inventor: Rebecca Lambert Bent
  • Patent number: 10189852
    Abstract: Processes for preparing oxymorphone are provided. Said processes encompass a step which is a hydrogenation of an 14-hydroxymorphinone salt in the presence of trifluoroacetic acid and/or a glycol.
    Type: Grant
    Filed: April 3, 2018
    Date of Patent: January 29, 2019
    Assignee: RHODES TECHNOLOGIES
    Inventors: Joshua Robert Giguere, Keith Edward McCarthy, Marcel Schleusner
  • Patent number: 10188643
    Abstract: The invention relates to a composition comprising buprenorphine and a ? opioid receptor antagonist, wherein the composition is characterized by an Agonist Antagonist Activity Index (AAnAI) of between about 0.7 and about 2.2; wherein; AAnAI = [ C max ? ( BUP ) / EC 50 ] [ C max ? ( ANTAGONIST ) / IC 50 ] .
    Type: Grant
    Filed: October 2, 2017
    Date of Patent: January 29, 2019
    Assignee: Alkermes Pharma Ireland Limited
    Inventors: Daniel Deaver, Elliot Ehrich
  • Patent number: 10172849
    Abstract: This disclosure relates to a buprenorphine sustained release delivery system for treatment of conditions ameliorated by buprenorphine compounds. The sustained release delivery system includes a flowable composition containing a suspension of buprenorphine, a metabolite, or a prodrug thereof.
    Type: Grant
    Filed: March 3, 2016
    Date of Patent: January 8, 2019
    Assignee: INDIVIOR UK LIMITED
    Inventors: Richard L. Norton, Mingxing Zhou
  • Patent number: 10154988
    Abstract: The invention relates to methods and compositions for treating schizophrenia or bipolar disorder (in particular, mania) by using a combination of a synaptic vesicle protein 2A (SV2A) inhibitor and an antipsychotic or their pharmaceutically acceptable salts, hydrates, solvates, polymorphs, and prodrugs thereof. The methods and the compositions can be used for treating one or more positive and/or negative symptoms, as well as cognitive impairment, associated with schizophrenia or bipolar disorder (in particular, mania).
    Type: Grant
    Filed: November 14, 2013
    Date of Patent: December 18, 2018
    Assignee: THE JOHNS HOPKINS UNIVERSITY
    Inventor: Michela Gallagher
  • Patent number: 10150775
    Abstract: Compounds of formula: in which R4 is chosen from substituted phenyl, optionally substituted naphthylene, optionally substituted anthracene and optionally substituted aromatic heterocycle, are useful as analgesics.
    Type: Grant
    Filed: August 8, 2017
    Date of Patent: December 11, 2018
    Assignee: Sloan-Kettering Institute for Cancer Research
    Inventors: Gavril Pasternak, Susruta Majumdar
  • Patent number: 10143792
    Abstract: Medicament delivery devices for administration of opioid antagonists are described herein. In some embodiments, an apparatus includes a housing, a medicament container disposed within the housing and an energy storage member disposed within the housing. The medicament container is filled with a naloxone composition that includes naloxone or salts thereof, a tonicity-adjusting agent, and a pH adjusting agent, whereby the osmolality of the naloxone composition ranges from about 250-350 mOsm and the pH ranges from about 3-5. The energy storage member is configured to produce a force to deliver the naloxone composition.
    Type: Grant
    Filed: October 21, 2016
    Date of Patent: December 4, 2018
    Assignee: kaleo, Inc.
    Inventors: Eric S. Edwards, Evan T. Edwards, Mark J. Licata, Frank E. Blondino
  • Patent number: 10130657
    Abstract: A formulation comprising platelet rich plasma (PRP) for treatment of patients who have experienced brain injury, consisting of a mixture of human autologous plasma, D5W, glutathione, methylcobalamin, and regular insulin. The formulation is infused directly adjacent to a patient's brain through the nostrils or nares of the nasal cavity. Treatment using the formulation may be supplemented with one or more therapies including hyperbaric oxidation therapy (HBOT), cranial osteopathic therapy, intravenous (IV) nutrition, electroencephalographic (EEG) biofeedback, low level laser therapy (LLLT), transcranial magnetic stimulation (TMS), adult stem cell treatments, and a ketogenic diet and medium-chain triglyceride (MCT) oil therapy.
    Type: Grant
    Filed: February 14, 2016
    Date of Patent: November 20, 2018
    Inventor: John C. Hughes
  • Patent number: 10131672
    Abstract: A therapeutic or prophylactic agent for biliary tract diseases includes as an effective component a specific compound having a morphinan skeleton represented by Compound 1, or a pharmaceutically acceptable acid addition salt thereof:
    Type: Grant
    Filed: January 28, 2011
    Date of Patent: November 20, 2018
    Assignee: Toray Industries, Inc.
    Inventors: Ryosuke Kobayashi, Kaoru Nakao
  • Patent number: 10064956
    Abstract: The presently described technology provides compositions comprising aryl carboxylic acids chemically conjugated to hydromorphone (4,5-?-epoxy-3-hydroxy-17-methyl morphinan-6-one) to form novel prodrugs/compositions of hydromorphone. The hydromorphone prodrugs of the present technology have decreased side effects and decreased potential for abuse compared to unconjugated hydromorphone. The present technology also provides methods of treating patients, pharmaceutical kits and methods of synthesizing conjugates of the present technology.
    Type: Grant
    Filed: November 14, 2017
    Date of Patent: September 4, 2018
    Assignee: KemPharm, Inc.
    Inventors: Travis Mickle, Sven Guenther, Guochen Chi, Jaroslaw Kanski, Andrea K. Martin, Bindu Bera
  • Patent number: 10045977
    Abstract: The present invention relates to new medical uses of morphinans such as nalmefene and naltrexone and their related derivatives, pharmaceutical formulations thereof, and use thereof for prevention and treatment of NASH, NAFLD, and/or ASH.
    Type: Grant
    Filed: April 20, 2017
    Date of Patent: August 14, 2018
    Assignee: TAIWANJ PHARMACEUTICALS CO., LTD.
    Inventors: Edwin S C Wu, Peter J. S. Chiu, May Mei-chi Hsu